Pfizer and Merck start PDL1-TKI combo trial for kidney cancer

Pfizer and Merck start PDL1-TKI combo trial for kidney cancer.

The Phama giants are beginning late-stage studies that will see a traditional TKI drug matched up with a new immunotherapy for renal cell carcinoma (RCC) patients.
Pfizer will bring its marketed kidney cancer drug Inlyta to the table while Darmstadt-based Merck will introduce its experimental anti-PD-L1 drug avelumab to the mix as a first-line treatment for patients with advanced RCC, a type of kidney cancer.
The two companies announced today that the first patient has been now been treated in the Phase III Javelin Renal 101 study. It is the first and only late-stage trial combining an anti-PD-L1 immunotherapy with a vascular endothelial growth factor (VEGF)-receptor TKI in this setting.
Read the full story here